CN110447892A - A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food - Google Patents

A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food Download PDF

Info

Publication number
CN110447892A
CN110447892A CN201910673589.4A CN201910673589A CN110447892A CN 110447892 A CN110447892 A CN 110447892A CN 201910673589 A CN201910673589 A CN 201910673589A CN 110447892 A CN110447892 A CN 110447892A
Authority
CN
China
Prior art keywords
food
amino acid
acid
hepatopathy
food according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910673589.4A
Other languages
Chinese (zh)
Inventor
高婷
张旗
张泽炎
陶秀梅
陈鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Nuobao Nutrition Technology Co ltd
Original Assignee
Beijing Nukangda Medicine Polytron Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Nukangda Medicine Polytron Technologies Inc filed Critical Beijing Nukangda Medicine Polytron Technologies Inc
Priority to CN201910673589.4A priority Critical patent/CN110447892A/en
Publication of CN110447892A publication Critical patent/CN110447892A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention belongs to special medicine purposes formula food fields, and in particular to a kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food.Contain 38~56g of carbohydrate, 11~22g of fat, 8~16g of protein, 9~25g of amino acid, compounding 0.5~3.0g of vitamin and compounding 4.0~10.0g of minerals in food described in every 100g.The present invention carries out more reasonable collocation according to the associated clinical symptoms for alleviating hepatic encephalopathy and Patients with Fatty Liver and the nutritional need and metabolic characteristic of promotion liver maintenance, to nutritional ingredient each in formula.

Description

A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food
Technical field
The invention belongs to special medicine purposes formula food fields, and in particular to a kind of special medicine purposes amino acid pattern liver Sick full nutrition formula food.
Background technique
Special medicine purposes formula food be obstructed to meet feed, Disorder of Digestion and A orption, metabolic disorder or specific disease The formula food being formulated specially is processed in special requirement of the diseased state crowd to nutrient or diet.Special medicine purposes is matched Square food is that food is not drug, cannot be prevented and treated to disease and clinical symptoms, but can provide nutritional support, is risen To the effect of nutrition " treatment ", there is immunoregulation, maintenance gastrointestinal function and structure, promote wound healing, improve patient's life Deposit the effects of rate shortens the hospital stays.About 40% inpatient is malnutritive or there are underfed risk, low income, It is malnutritive more universal with chronic disease, for a long time or in the serious patient with pain.
China is hepatopathy big country, and pathogenesis of cirrhosis rate is high, and hepatic encephalopathy and fatty liver are the complication of cirrhosis most serious, It refers to that the death rate is high by metabolism is caused, reversible, brain dysfunction syndrome prognosis is poor, makes to hospital and country At serious financial burden.
Hepatic encephalopathy and the still difficult assessment of the exact incidence of fatty liver, most liver cirrhosis patients are certain in the course of disease Stage will appear different degrees of hepatic encephalopathy and fatty liver.According to foreign data, liver cirrhosis patient is with hepatic encephalopathy and rouge The incidence of fat liver is at least 30%~45%, and in the progression of disease phase, its incidence may be higher.The hepatic encephalopathy of China's report It is differed with fatty liver incidence from 10% to 50%.Recently, Chinese Medical Association's disease for digest credit meeting disease in the liver and gallbladder cooperative groups are to complete 13 provinces and cities, state, 16 tertiary hospitals of autonomous region be hospitalized 519 liver cirrhosis patients (63% is caused by chronic hepatitis B) into Row investigation, with NCT-A and digit symbol test, both abnormity diagnosis is slight type hepatic encephalopathy and fatty liver, as the result is shown gently The incidence of miniature hepatic encephalopathy and fatty liver is 39.9%, wherein the slight type hepatic encephalopathy of Child-Pugh A grade person and fat It is 39.4%, C grade person is 56.1% that liver incidence, which is 24.8%, B grade person,.The generation and disease of slight type hepatic encephalopathy and fatty liver Because of being not significantly related to property, but with the exacerbation of Decompensated liver cirrhosis degree, incidence increases, and has slight type liver property brain A possibility that patient evolution of disease and fatty liver medical history is hepatic encephalopathy and fatty liver is big.
Current main hepatopathy nutritional preparation product is mostly or from foreign countries, and such hepatopathy nutrition product is predominantly whole Protein type or short peptide type.Most products, mostly single active ingredient on the market, major function are to remove free radical, change Kind chemical damage etc., is not able to satisfy the nutritional need of hepatic encephalopathy and Patients with Fatty Liver, and such product cost is high, sells Valence exceeds most crowd's ability to shoulder economicallies.
In consideration of it, the present invention is specifically proposed.
Summary of the invention
Goal of the invention of the invention is to propose a kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food
In order to complete the purpose of the present invention, the technical solution of use are as follows:
The present invention proposes a kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food, in food described in every 100g Containing 38~56g of carbohydrate, 11~22g of fat, 8~16g of protein, 9~25g of amino acid, compounding vitamin 0.5~ 3.0g and compounding 4.0~10.0g of minerals；Wherein, 2~6g containing dietary fiber in carbohydrate；The carbohydrate packet Maltodextrin and isomaltoketose are included, the dietary fiber includes water-soluble dietary fiber and insoluble diedairy fiber；The rouge Fat is the combination of safflower seed oil microcapsule powder, linseed oil microcapsule powder and medium chain triglyceride microcapsule powder, and the protein includes big Beans protein isolate, hydrolyzing lactoalbumin；Contain leucine, isoleucine, valine, L-aminobutanedioic acid and bird ammonia in the amino acid Acid.
Optionally, 1~3g of leucine, 1~3g of isoleucine, 1~3g of valine, Men Dong are contained in food described in every 100g 3~8g of propylhomoserin, 3~8g of ornithine.
Optionally, water-soluble dietary fiber is selected from resistant dextrin, and insoluble diedairy fiber is selected from resistant starch；Preferably, The mass ratio of resistant dextrin and resistant starch is 1.5~2.5:1, more preferably 1.8~2.2:1.
Optionally, the mass ratio of maltodextrin and isomaltoketose is 0.5~1.5:1, preferably 0.8~1.2:1.
Optionally, 4~8g of soybean protein isolate, 4~8g of hydrolyzing lactoalbumin are contained in food described in 100g.
Optionally, energy supply ratio fatty in the food is no more than 30%, it is preferred that unsaturated fatty acid accounts for the total matter of fat The 20%~35% of amount.
Optionally, in food described in every 100g containing 2~6g of safflower seed oil microcapsule powder, 1~4g of linseed oil microcapsule powder, in 8~12g of chain triglyceride microcapsule powder.
Optionally, corrigent and acidity regulator are also contained in the food, the corrigent is selected from sweetener and fragrance Agent, the acidity regulator are selected from citric acid；Preferably, the sweetener is in composite sweetener, the composite sweetener Contain glucose, Aspartame, acesulfame potassium；The aromatic is selected from orange flavor, mango essence.
Optionally, the additive amount of the sweetener is the 0.4%~0.5% of the food, preferably 0.4%~0.45%； The additive amount of the acidity regulator is the 1.0%~1.1% of the food；It is preferred that 1.05%~1.08%；The aromatic Additive amount be the food 0.1%~0.25%, preferably 0.2%~0.25%.
Optionally, the preparation of the food is selected from least one of powder, granule, capsule, tablet and emulsion；It is excellent Choosing, when preparation is selected from powder, granule, corrigent and acidity regulator are individually packed.
Technical solution of the present invention at least has following beneficial effect:
The present invention is according to the associated clinical symptoms for alleviating hepatic encephalopathy and Patients with Fatty Liver and the nutrition of promotion liver maintenance Demand and metabolic characteristic carry out more reasonable collocation to nutritional ingredient each in formula.By adding dietary fiber, liver is controlled The blood glucose of patient, while improving hepatopath's intestinal health.Amino acid, soybean protein isolate, hydrolyzed whey egg are added simultaneously It is white to help to mitigate gastrointestinal tract burden, it can be used for associated clinical symptoms and the promotion of alleviating hepatic encephalopathy and Patients with Fatty Liver Liver maintenance.Optimization fat proportion does not aggravate the digestion burden of hepatopath, meets the essential fatty acid demand of body.
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention Rather than it limits the scope of the invention.
Specific embodiment
The embodiment of the present invention proposes a kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food, every 100g food In containing 38~56g of carbohydrate, 11~22g of fat, 8~16g of protein, 9~25g of amino acid, compound vitamin 0.5~ 3.0g and compounding 4.0~10.0g of minerals；Wherein, 2~6g containing dietary fiber in carbohydrate.The embodiment of the present invention it is complete The carbohydrate and dietary fiber that rational proportion adds in nutritional formulas, dietary fiber can effectively improve glycometabolism, Postprandial blood sugar, lowering blood pressure and blood fat are reduced, satiety is increased and prevents constipation.Water-soluble dietary fiber can meet water in gastrointestinal tract Viscose is formed with glucose afterwards and slows down sugared absorption, is that postprandial blood sugar and the horizontal of insulin reduce, and have reduction simultaneously The effect of cholesterol absorption.Non-soluble dietary fiber can be in enteron aisle adsorption moisture, and formation is network-like, makes food and digestive juice not It can come into full contact with, therefore starch digestion and absorption slows down, and can lower postprandial blood sugar, blood lipid, increases satiety and softer stool.To liver The glycemic control of patient is beneficial, and the generally existing pathoglycemia of hepatopath, clinical manifestation is hyperglycemia, and the control of blood glucose is very heavy It wants, while beneficial to hepatopath's intestinal health.Nitrogen source is in the hepatopathy full nutrition formula food of the embodiment of the present invention with amino The form of acid, soybean protein isolate and lactalbumin exists, and helps to mitigate gastrointestinal tract burden.Optimization fat proportion, is not aggravated The digestion of patient is born, and the essential fatty acid demand of body is met.Amino acid includes leucine, isoleucine and three kinds of valine Branched-chain amino acid, and the L-aminobutanedioic acid with immune function, ornithine etc. be used as functional component, have correct hepatic encephalopathy and Patients with Fatty Liver Hypoproteinemia, the effect for promoting liver cell to repair.
Main carbohydrate source first is that maltodextrin, is to be made from starch, through enzyme process in the embodiment of the present invention Minuent hydrolysis, purification, the manufactured starch derivatives for being free of free starch of spray drying, are widely used in as carbohydrate In varieties of food items, the report for having adverse reaction to human body is had no, execution standard is GB/T 20884.Another part carbon hydrate Object is isomaltoketose (isomaltulose), also known as palatinose, isomery sucrose, using white granulated sugar as raw material, through sucrose isomerase Enzymatic conversion, then it is concentrated, crystallize, separate.Isomaltoketose has energy identical with sucrose, but only in human small intestine Be decomposed absorption, and decomposes the speed absorbed and there was only 1/5th of sucrose, therefore can continue, offer slowly, balanced Blood glucose also can be effectively controlled to improve persistently movement, antifatigue ability in energy.Isomaltoketose sugariness is moderate, can adjust The mouthfeel of whole formula.
Optionally, the mass ratio of maltodextrin and isomaltoketose be 0.5~1.5:1, preferably 0.8~1.2:1, it is more excellent It is selected as 1:1.The embodiment of the present invention it has been investigated that, using the ratio, mouthfeel is best, and product osmotic pressure is moderate, clinical compliance Good, have no adverse reaction appearance.
The dietary fiber of the embodiment of the present invention includes water-soluble dietary fiber and insoluble diedairy fiber；Aqueous soluble dietary is fine The cooperation of peacekeeping insoluble diedairy fiber can be effectively controlled blood glucose, improve constipation.
Optionally, water-soluble dietary fiber is selected from resistant dextrin, and insoluble diedairy fiber is selected from resistant starch.Resistant dextrin It is process by starch, is a kind of low-heat made of baking the indigestibility ingredient industrial technology extraction process of dextrin and refining Glucan is measured, low molecule water-soluble dietary fiber is belonged to.Since it contains human body digestive ferment (such as amylase, glucoamylase Enzyme etc.) effect indigestibility ingredient, absorptions will not be digested in alimentary canal, can be directly entered large intestine, therefore it is that one kind is low Calorie foodstuffs raw material can be used as dietary fiber and play various physiological actions.Experiment can obviously inhibit after showing edible resistant dextrin The rising of blood glucose and insulin.This is because resistant dextrin can delay and inhibit digestion and absorption of the small intestine to carbohydrate, and improve end Tip tissue reduces the demand to insulin to the sensitivity of insulin.Water-soluble resistant dextrin is prevented with the formation of gel The diffusion of carbohydrate, has postponed the absorption of carbohydrate in the intestine, thus the rising of blood glucose and blood insulin after inhibiting carbohydrate to absorb Raised reaction.Furthermore resistant dextrin can change the secretion of intestinal hormone, such as reduce the secretion of pancreatic secretion, to inhibit sugar The absorption of class；Resistant dextrin can also adjust organism metabolism activity by changing the digested enzymatic activity of enteron aisle；Resistant dextrin also has Play the role of inhibiting amylase to starch, extends enzyme effect in the time of starch, make the release of glucose sugar slowly, to play reduction The effect of blood glucose.Resistant starch category polysaccharose substance, physiological function and dietary fiber very phase very useful to human health Seemingly, but compared to dietary fiber, there are many different advantages again.Its physiological action mainly has: control weight and energy balance, drop The onset risks such as low hyperlipidemia, atherosclerosis and obesity；Enteric microorganism bacterium can be adjusted by bacterial fermentation in large intestine Group generates short chain fatty acids (SCFA) beneficial to human health, inhibits pathogenic bacteria growth, breeding, reduce intestines dysfunction and The disease incidence of carcinoma of cecum, colon cancer: control postprandial blood sugar and insulin level can efficiently control diabetic condition；Promote intestines The wriggling in road enhances the resistance to diseases such as constipation, diarrhea, typhlitis, hemorrhoid；Promote the absorption of vitamin, minerals；It is good Good Bifidobacterium proliferation factor.
Preferably, the mass ratio of resistant dextrin and resistant starch be 1.5~2.5:1, more preferably 1.8~2.2:1, it is optimal It is selected as 2:1.Using the ratio of the embodiment of the present invention, while reducing the intake of water-soluble dietary fiber, insoluble diet is fine Dimension can excrete internal harmful substance, can reduce fat, cholesterol level.By clinical experimental study, using the ratio The constipation situation of hepatopath can be effectively relieved, and effectively control blood glucose, triacylglycerol and cholesterol.Specifically, fat is packet Include the composition of safflower seed oil microcapsule powder, linseed oil microcapsule powder, medium chain triglyceride microcapsule powder.Safflower oil belongs to height insatiable hunger With fatty acid oils, linoleic acid content is up to 80% or more, can reduce blood lipid and cholesterol and plays medical care effect.It is sub- Oleic acid is that a kind of human body itself cannot synthesize, it is necessary to which the essential fatty acid obtained by diet is that 18 carbon long-chain of one kind is unsaturated ω -6 fatty acid.Linoleic acid belongs to the maternal fatty acid of ω -6 fatty acid, and body can use maternal fatty acid synthesis more long-chain Fatty acid, such as arachidonic acid.For linoleic acid as the essential fatty acid being identified earliest, having reduces serum cholesterol water Flat effect, taking in a large amount of linoleic acid has apparent effect to high triglyceride patient population.Linoleic acid is to hypertension, high blood The prevention and treatment of rouge, angina pectoris, atherosclerosis, senile obesity etc. is extremely advantageous, and can play prevents human serum cholesterol In the deposition of vascular wall, there is the good reputation of " blood vessel scavenger ".Linseed oil is the current highest vegetable oil of omega-fatty acid content One of rouge, the content of alpha-linolenic acid are about 45%-65%.Alpha-linolenic acid is as linoleic acid and a kind of essential fatty acid, people Body cannot synthesize, it is necessary to absorb and obtain from food.Alpha-linolenic acid belongs to the maternal fatty acid of omega-fatty acid, and body can benefit ω -3 race the fatty acid of more long-chain, such as DHA and EPA are synthesized with linolenic acid.Alpha-linolenic acid has reduction blood lipid, reduces blood pressure, in advance Prevent cardiovascular effect, strengthen immunity with it is anti-inflammatory.So adding safflower oil and linseed oil in this formula, meet body pair The demand of necessary fatty acid.
The protein of the embodiment of the present invention includes soybean protein isolate, hydrolyzing lactoalbumin.Wherein, hydrolyzing lactoalbumin is former The content of branched-chain amino acid (BCAA) is up to 25% in material.Branched-chain amino acid is a kind of useful energy source, can by skeletal muscle, Cardiac muscle, brain, liver (may be there are also its hetero-organization) directly utilize.In muscle, branched-chain amino acid can be used as exercise and stress shape Energy matter under state, it may have the potentiality of encephalopathy occur for prevention hepatic failure patients.Branched-chain amino acid (especially leucine) is Human growth factors generate and the potential stimulus object of liver regeneration, can satisfy nutritional need, improve Child-Pugh scoring.Branch Liver cirrhosis patient protein breakdown situation can also be effectively reduced in amino acid supplements, improve nitrogen balance.Dyshepatia patient is equal There is disorder of amino acid metabolism, the branched-aminos acid concentration such as leucine, isoleucine, valine reduces in blood, and at the same time, Since hepatosis cannot be into the aromatic amino acids such as tyrosine, phenylalanine (AAA, aromatic amino acid) Row processing cannot be handled sufficiently, thus aromatic amino acid blood level obviously increases, and can cause intracerebral aromatic series amino Acid and its metabolite increase and nervous symptoms or even stupor occur.Therefore, to dyshepatia especially hepatic coma or liver property Encephalopathy patient should select the nutrients containing branched-chain amino acids such as leucine, isoleucine, valines.Hinder in hepatocyte function When hindering, amino acid metabolism is affected, and phenylalanine raising, the decline of BCAA/AAA ratio occurs, and blood ammonia increases phenomenon.To be rich in The compound amino acid supplement of BCAA is beneficial to mitigate the burden of liver, adjusts blood plasma BCAA/AAA ratio as nitrogen source, prevent and Hepatic encephalopathy is corrected, skeletal muscle protein is reduced and decomposes, improves protein synthesis.Soybean protein isolate is quality plant albumen, Hydrolyzing lactoalbumin is high-quality animal protein, and albumen source is high-quality protein, is easily absorbed.Soybean protein contains 16 kinds of amino Acid is the protein known today uniquely containing 9 kinds of essential amino acids.Hydrolyzing lactoalbumin then contains needed by human 8 kinds Amino acid, and branched-chain amino acid rich content.Since different proteins amino acid compositional model and type are different, advanced knot in addition The difference of structure causes different proteins amino acid rate of release and mode in digestion process to be not quite similar, and carries out " double protein " It is the effective way for strengthening animal/vegetable protein complementation.
Optionally, the special medicine purposes amino acid pattern hepatopathy full nutrition formula food of the embodiment of the present invention contains in 100g There are 4~8g of soybean protein isolate, 4~8g of hydrolyzing lactoalbumin.Contain leucine, different bright ammonia in the amino acid of the embodiment of the present invention Acid, valine, L-aminobutanedioic acid and ornithine.L-aminobutanedioic acid, ornithine have as main free amino acid source in formula Promote hepatic encephalopathy and the synthesis of Patients with Fatty Liver vivo protein, correct the ratio of aromatic amino acid and branched-chain amino acid, promotees Into the conversion of internal ammonia, the blood ammonia levels of patient's body are reduced.Branched-chain amino acid includes valine, leucine and isoleucine. Branched-chain amino acid especially leucine, can be synthesized with stimulating protein, inhibit breaks down proteins, promote glutamine synthesis.This Outside, branched-chain amino acid can stimulate mononuclear cell proliferation, adjust the secretion of cell factor, promote the development of Th1 type immune response.This Outer branched-chain amino acid can promote wound skin collagen hyperplasia and accelerate skin healing.
Optionally, the special medicine purposes amino acid pattern hepatopathy full nutrition formula food of the embodiment of the present invention, in every 100g Contain 1~3g of leucine, 1~3g of isoleucine, 1~3g of valine, 3~8g of L-aminobutanedioic acid, 3~8g of ornithine.Using this ratio The amino acid of example is conducive to mitigate the burden of liver, adjusts blood plasma BCAA/AAA ratio, prevents and correct hepatic encephalopathy, reduces bone Myoprotein decomposes, and improves protein synthesis.
Optionally, energy supply ratio fatty in the food of the embodiment of the present invention is no more than 30%.If fat energy supply is excessively high There are the risks such as lipidosis, loss of appetite, with the increase of fatty energy supply ratio, crowd's overweight/obesity rate, 2 type glycosurias Sick illness rate and blood cholesterol levels increase therewith；Deficiency is energized if fat energy supply is too low, malnutritive incidence is high.
Optionally, unsaturated fatty acid accounts for the 20%~35% of fatty gross mass, and the molecular structure of saturated fatty acid is stiff It lacks flexibility, if cell constitutes cell membrane with a large amount of saturated fatty acids, can make originally can be with free flow as water Dynamic cell membrane solidification, unsaturated fatty acid can not only constitute the cell membrane of health, additionally it is possible to repair saturated fatty acid to us Caused by injure.The low i.e. saturated fatty acid ratio of unsaturated fatty acid ratio is high, and saturated fatty acid energy supply rapidly, can excessively accumulate In vivo, the incidence of various chronic diseases is caused to increase, such as diabetes, hyperlipidemia, obesity；Unsaturated fatty acid unsaturated lipid The excessively high intake of fat acid ratio is excessive may then to have a negative impact to immune.
Optionally, the special medicine purposes amino acid pattern hepatopathy full nutrition formula food of the embodiment of the present invention, in every 100g Contain 2~6g of safflower seed oil microcapsule powder, 1~4g of linseed oil microcapsule powder, 8~12g of medium chain triglyceride microcapsule powder.
Optionally, vitamin A, vitamin are contained in the compounding vitamin in the full nutrition formula food of the embodiment of the present invention D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, folic acid, pantothenic acid, vitamin C, Biotin, choline and taurine.
Optionally, in the compounding minerals in the full nutrition formula food of the embodiment of the present invention containing sodium, potassium, copper, magnesium, Iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium.
Specifically, the composition of the full nutrition formula food of the present embodiment is as shown in table 1:
Table 1
Optionally, corrigent and acidity regulator are also contained in the food of the embodiment of the present invention, place is seasoned to product Reason solves the problems, such as the taste of original flavor product and has a poor flavour.
Specifically, corrigent is selected from sweetener and aromatic, acidity regulator is selected from citric acid；Preferably, sweetener selects Contain glucose, Aspartame, acesulfame potassium from composite sweetener, composite sweetener；Specific mass ratio are as follows: glucose: A Si Ba Tian: acesulfame potassium=3.5~2:1.5~0.8:1.5~0.8.Aromatic is selected from orange flavor, mango essence.
Optionally, the additive amount of sweetener is the 0.4%~0.5% of the food, preferably 0.4%~0.45%；It is optional , the additive amount of acidity regulator is the 1.0%~1.1% of the food, preferably 1.05%~1.08%；Optionally, fragrant The additive amount of agent is the 0.1%~0.25% of the food, preferably 0.2%~0.25%.The embodiment of the present invention passes through to sweet taste Agent, the further investigation of acidity regulator and aromatic ratio, improve the mouthfeel of product.This is for special medicine purposes food It is a highly important improvement, since the raw material added in food is with bad smell, for oral, compliance is very Difference, the embodiment of the present invention improve the compliance of product by the improvement to taste.
The preparation of food of the embodiment of the present invention is selected from least one of powder, granule, capsule, tablet and emulsion. When preparation is selected from powder, granule, corrigent and acidity regulator are individually packed, and the difference of mode is taken so as to basis, Such as oral and tube feed, selectivity addition seasoning packet.
Technical solution provided by the invention is described in detail below with reference to embodiment, but they cannot be understood For limiting the scope of the present invention.
Embodiment 1
A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food, concrete composition are as shown in table 2:
Table 2
Formulated food additive (vitamin) each component content in above-mentioned formula is shown in Table 3.
Each component content in 3 formulated food additive (vitamin) of table
Material name Additive amount g/100g
Retinol acetate 0.00513
Vitamin D3 0.00304
Dl- α-D-α-tocopherol acetate 0.03129
Phytondione 0.00080
Thiamine hydrochloride 0.00367
Riboflavin 0.00280
Puridoxine hydrochloride 0.00341
Cyanocobalamin 0.00450
Niacinamide 0.00684
Folic acid 0.00520
D-VB5 calcium 0.01115
L-AA sodium 0.39370
D-Biotin 0.01050
Choline bitartrate 0.38618
Potassium iodide 0.00068
Maltodextrin (auxiliary material) 0.58110
Taurine 0.05000
Each component content is shown in Table 4 in formulated food additive (minerals) in above-mentioned formula.
Each component content in 4 formulated food additive (minerals) of table
Embodiment 2
A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food, concrete composition are as shown in table 5:
Table 5
Each component contains in formulated food additive (minerals) and formulated food additive (vitamin) in above-mentioned formula Amount is shown in Table 3 and table 4.
Influence experiment of the experimental example 1 to hepatic encephalopathy and Rats with Fatty Liver
The resulting special medicine purposes amino acid pattern hepatopathy full nutrition formula food of the embodiment of the present invention 1~3 is taken to be tried It tests, while setting control group, control carries out Nutritional support.
The preparation of nutrient solution:
(1) control group: every 100mL Long-chain triglycerides in the 20% of 6mL, 7% amino acid of 53mL, 39mL 50% glucose solution and suitable vitamin are formulated.
(2) experimental group: using 1~3 gained formula food of inventive embodiments, and every part is made 300mL's with the dissolution of 250 warm waters Solution.The every 100mL nitrogen content of above-mentioned nutrient solution and heat are almost the same.
Experimental method:
40 (SPF grades) of 200~240g male SD rat fill rat using high spirit and fatty liver method are caused to prepare rouge Fat hepatomegaly mouse model.The above rat is divided into two groups of control group and experimental group, every group 20.Control group and experiment after modeling Group gives corresponding nutritional support 2 weeks (300kcal/kg) according to above-mentioned nutrient solution respectively, and nutrient solution is using intravenous injection.Finally Weight gain, survival rate and the immunity of organism activity of survey calculation each group rat.All data are indicated with Mean ± SD, are used Minitab 17.1.0 software carries out one-way analysis of variance, further with Turkey Multiple range test determine each group of data between it is aobvious Sex differernce is write, the level of signifiance is set as p < 0.05.
Influence to rat body weight the results are shown in Table 5.
Table 5: the influence to rat body weight
Group First weight/g Whole weight/g Weight gain/g
Experimental group 220±10 260±6 38±7
Control group 223±8 270±8 42±10
As shown in Table 5, compared with the control group, there was no significant difference (P > 0.05) for the weight gain of control rats, thus As it can be seen that sample does not have significant difference to the body weight increase of rat, its normal physiological function can be maintained.
After 2 weeks, the survival rate of control rats is 68%, and the survival rate of experimental group is 79%, so spy of the invention The survival rate of hepatic encephalopathy and Rats with Fatty Liver can be improved in different medical usage formula food.
After 2 weeks, portal vein and Inferior Vena Cava Blood are acquired, detects tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), c reactive protein (CRP) and T lymphocyte sum, the results are shown in Table 6.
Table 6: serum cytokines and lymphocyte compare after two weeks for nutritional support
As shown in Table 6, control group and experimental group TNF-α level be without significant difference (P > 0.05), but the IL-6 of experimental group and CRP level is substantially less than control group (P > 0.05), so the inflammation that acute pancreatitis in rats can be significantly reduced in the present invention is anti- It answers.Control group and experimental group CD8+ level are without significant difference (P > 0.05), but CD8+ the and CD4+/CD8+ level of experimental group is aobvious It writes and is higher than control group (P > 0.05), illustrate that the present invention can improve body by increasing the quantity of body periphery lymphocyte Cellular immune function.So Immune Function can be improved in the present invention, and then reduce the inflammatory reaction of body.
Embodiment 2: the improvement to hepatic encephalopathy and Patients with Fatty Liver nutrition condition
The resulting special medicine purposes amino acid pattern hepatopathy full nutrition formula food of the embodiment of the present invention 1~3 is taken to be faced Bed test, while control group is set, control carries out Nutritional support.
The preparation of nutrient solution:
(1) control group: every 100mL Long-chain triglycerides in the 20% of 6mL, 7% amino acid of 53mL, 39mL 50% glucose solution and suitable vitamin are formulated.
(2) experimental group: using 1~3 gained formula food of inventive embodiments, and every part is made 300mL's with the dissolution of 250 warm waters Solution.The every 100mL nitrogen content of above-mentioned nutrient solution and heat are almost the same.
60 hepatic encephalopathies, male 37, all meet in " Chinese hepatopathy diagnosis and treatment guide (draft) " standard by female 23 Diagnosis.The above patient is randomly divided into control group and experimental group, gives nutritional support 3 weeks according to 25kcal/ (kg*d).Control Group gives parenteral nutrition by central vein, and the intestinal nutrient solution of experimental group is given by nasointestinal tube.
Evaluation index: a weight, albumin and prealbumin concentration are measured weekly to assess nutritional status.It measures weekly CRP, an IL-6 and TNF-α assess the inflammatory conditions of patient.It is horizontal that CD8+, CD8+ and a CD4+/CD8+ are measured weekly To assess the immune state of body.All data are indicated with Mean ± SD, carry out single factor test using Minitab 17.1.0 software Variance analysis, further with Turkey Multiple range test determine each group of data between significant difference, the level of signifiance be set as p < 0.05。
The weight of patient is influenced as shown in table 7.
Table 7: the influence to patient's weight
Group 1d 7d 14d 21d
Experimental group 58.2±5.2 57.3±6.2 56.4±9.5 58.3±4.1
Control group 60.2±5.9 56.8±5.3 54.9±4.2 51.2±5.7
During nutritional intervention, the weight presentation of experimental group falls before rear raised trend, and overall variation is smaller；And it is right According to group then it is presented the trend being gradually reduced, after intervening 3 weeks, weight loss about 9kg.So compared with parenteral nutrition, the present invention It can maintain the weight of hepatic encephalopathy.
Influence to the albumin and prealbumin of patient is as shown in table 8.
Table 8: the influence to the albumin and prealbumin of patient
During nutritional intervention, the trend being gradually increased is presented in the albumin of experimental group and control group, but the two does not have Marked difference.The prealbumin content of experimental group 21d is significant compared with before experiment to increase (p < 0.05).Illustrate that the present invention can be with Patients serum's albumin content is increased, its nutritional status is improved.
Special medicine purposes amino acid pattern hepatopathy full nutrition formula food to the tumor necrosis factor-alpha (TNF-α) of patient, The influence of interleukin-6 (IL-6), c reactive protein (CRP) and T lymphocyte sum is shown in Table 9.
Table 9: the influence to patient's inflammatory factor and lymphocyte
Becoming for reduction is presented in experimental group and the horizontal of the Serum TNF-α of control group, IL-6 and CRP as time went on Gesture, and the downward trend of the TNF-α of experimental group, IL-6 level is more significant.The CD4+/CD8+ presentation of experimental group gradually increases Trend, and the trend gradually decreased is then presented in control group.So the present invention can reduce body and be put into inflammatory reaction, pass through increasing Body lymphocyte quantity is added to increase immunity of organism.
From above-mentioned zoopery and clinical test: the present invention can significantly improve the nutritional status of body, maintain machine The normal physiological function of body.The inflammatory reaction state of hepatic encephalopathy can be significantly reduced in the present invention, while by increasing leaching Bar cell quantity increases the immunity of body, facilitates the quality of life for improving patient, it helps the later period rehabilitation of patient.
3 glycemic control of experimental example
60 people for being diagnosed as fatty liver merging diabetes B are divided by test group using double-blind study and control group is tested Research, 30 people of test group, each 15 people of men and women patient；30 people of control group, male patient 17, female patient 13.Test group is produced with this Product carry out dietary therapy, and control group carries out routine care, carry out blood glucose, triacylglycerol, cholesterol and high density to two groups of patients The indexs of correlation situation of change such as lipoprotein compares, experimental result such as table 10.
Table 10: the influence to blood glucose
Note: * P < 0.05.
10 experimental result of table shows that the testing result of each index of test group is superior to control group.It is of the invention special to illustrate Medical usage amino acid pattern hepatopathy full nutrition formula food can improve the blood glucose of Patients with Fatty Liver.
It is not for limiting claim, any this field skill although the present invention is disclosed as above with preferred embodiment Art personnel without departing from the inventive concept of the premise, can make several possible variations and modification, therefore of the invention Protection scope should be subject to the range that the claims in the present invention are defined.

Claims (10)

1. a kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food, which is characterized in that in food described in every 100g Containing 38~56g of carbohydrate, 11~22g of fat, 8~16g of protein, 9~25g of amino acid, compounding vitamin 0.5~ 3.0g and compounding 4.0~10.0g of minerals；
Wherein, 2~6g containing dietary fiber in the carbohydrate；The carbohydrate includes maltodextrin and different malt ketone Sugar, the dietary fiber include water-soluble dietary fiber and insoluble diedairy fiber；
The fat is the combination of safflower seed oil microcapsule powder, linseed oil microcapsule powder and medium chain triglyceride microcapsule powder,
The protein includes soybean protein isolate, hydrolyzing lactoalbumin；
Contain leucine, isoleucine, valine, L-aminobutanedioic acid and ornithine in the amino acid.
2. food according to claim 1, which is characterized in that contain 1~3g of leucine, different bright in food described in every 100g 1~3g of propylhomoserin, 1~3g of valine, 3~8g of L-aminobutanedioic acid, 3~8g of ornithine.
3. food according to claim 1, which is characterized in that water-soluble dietary fiber is selected from resistant dextrin, insoluble meals It eats fiber and is selected from resistant starch；
Preferably, the mass ratio of resistant dextrin and resistant starch is 1.5~2.5:1, more preferably 1.8~2.2:1.
4. food according to claim 1, which is characterized in that the mass ratio of maltodextrin and isomaltoketose be 0.5~ 1.5:1, preferably 0.8~1.2:1.
5. food according to claim 1, which is characterized in that in food described in 100g containing 4~8g of soybean protein isolate, 4~8g of hydrolyzing lactoalbumin.
6. food according to claim 1, which is characterized in that fatty energy supply ratio is no more than 30% in the food；
Preferably, unsaturated fatty acid accounts for the 20%~35% of fatty gross mass.
7. food according to claim 6, which is characterized in that in the composition, contain safflower in food described in every 100g 2~6g of seed oil microcapsule powder, 1~4g of linseed oil microcapsule powder, 8~12g of medium chain triglyceride microcapsule powder.
8. food according to claim 1, which is characterized in that also contain corrigent and acidity regulator, institute in the food It states corrigent and is selected from sweetener and aromatic, the acidity regulator is selected from citric acid；
Preferably, the sweetener is selected from composite sweetener, contains glucose, Aspartame, An Sai in the composite sweetener Honey；
The aromatic is selected from orange flavor, mango essence.
9. food according to claim 8, which is characterized in that the additive amount of the sweetener be the food 0.4%~ 0.5%, preferably 0.4%~0.45%；
The additive amount of the acidity regulator is the 1.0%~1.1% of the food；It is preferred that 1.05%~1.08%；
The additive amount of the aromatic is the 0.1%~0.25% of the food, preferably 0.2%~0.25%.
10. food according to claim 1, which is characterized in that the preparation of the food be selected from powder, granule, capsule, At least one of tablet and emulsion；
Preferably, when preparation is selected from powder, granule, corrigent and acidity regulator are individually packed.
CN201910673589.4A 2019-07-24 2019-07-24 A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food Pending CN110447892A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910673589.4A CN110447892A (en) 2019-07-24 2019-07-24 A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910673589.4A CN110447892A (en) 2019-07-24 2019-07-24 A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food

Publications (1)

Publication Number Publication Date
CN110447892A true CN110447892A (en) 2019-11-15

Family

ID=68483341

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910673589.4A Pending CN110447892A (en) 2019-07-24 2019-07-24 A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food

Country Status (1)

Country Link
CN (1) CN110447892A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111227235A (en) * 2020-03-05 2020-06-05 北京诺康达医药科技股份有限公司 Total-nutrient formula food for liver diseases and preparation method and application thereof
CN113615832A (en) * 2021-09-02 2021-11-09 西安交通大学医学院第一附属医院 Composition suitable for convalescent period of hyperlipemia type acute pancreatitis patient and preparation method thereof
CN113632977A (en) * 2021-08-31 2021-11-12 西安交通大学医学院第一附属医院 Dietary composition suitable for pregnant women with pregnancy complicated with hepatitis and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
CN103446166A (en) * 2012-05-29 2013-12-18 上野制药株式会社 Liver function-improving agent
CN105558046A (en) * 2016-01-12 2016-05-11 刘保惠 Formula food with special medicinal purpose and suitable for liver disease and preparation method thereof
CN105942506A (en) * 2016-05-19 2016-09-21 华隆（乳山）食品工业有限公司 Special medical application formula food suitable for patients suffering from liver diseases
CN106605908A (en) * 2016-05-27 2017-05-03 韶关邦世迪健康实业有限公司 Fully nutritional formula product with special medical purposes for liver diseases
CN108294306A (en) * 2018-04-03 2018-07-20 健行天下生物技术有限公司 A kind of full nutrition special medicine purposes formula food of amino acid pattern

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
CN103446166A (en) * 2012-05-29 2013-12-18 上野制药株式会社 Liver function-improving agent
CN105558046A (en) * 2016-01-12 2016-05-11 刘保惠 Formula food with special medicinal purpose and suitable for liver disease and preparation method thereof
CN105942506A (en) * 2016-05-19 2016-09-21 华隆（乳山）食品工业有限公司 Special medical application formula food suitable for patients suffering from liver diseases
CN106605908A (en) * 2016-05-27 2017-05-03 韶关邦世迪健康实业有限公司 Fully nutritional formula product with special medical purposes for liver diseases
CN108294306A (en) * 2018-04-03 2018-07-20 健行天下生物技术有限公司 A kind of full nutrition special medicine purposes formula food of amino acid pattern

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘百舸等: "支链氨基酸联合门冬氨酸鸟氨酸治疗肝性脑病的疗效观察", 《中国实用神经疾病杂志》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111227235A (en) * 2020-03-05 2020-06-05 北京诺康达医药科技股份有限公司 Total-nutrient formula food for liver diseases and preparation method and application thereof
CN111227235B (en) * 2020-03-05 2022-09-02 北京诺葆营养科技有限公司 Total-nutrient formula food for liver diseases and preparation method and application thereof
CN113632977A (en) * 2021-08-31 2021-11-12 西安交通大学医学院第一附属医院 Dietary composition suitable for pregnant women with pregnancy complicated with hepatitis and preparation method thereof
CN113632977B (en) * 2021-08-31 2023-09-19 西安交通大学医学院第一附属医院 Dietary composition suitable for pregnant women with pregnancy-associated hepatitis and preparation method thereof
CN113615832A (en) * 2021-09-02 2021-11-09 西安交通大学医学院第一附属医院 Composition suitable for convalescent period of hyperlipemia type acute pancreatitis patient and preparation method thereof
CN113615832B (en) * 2021-09-02 2024-03-05 西安交通大学医学院第一附属医院 Composition suitable for recovery period of patient with hyperlipidemia type acute pancreatitis and preparation method thereof

Similar Documents

Publication Publication Date Title
JP4699901B2 (en) Dietary additive with body fat metabolism function and combustion energy utilization function
CN104812254B (en) Dietary fiber for the gastrointestinal side-effect for treating nutrients or medicament
CN103458891A (en) Nutritional composition
CN107319525A (en) One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof
CN110810845A (en) Total nutrient formula powder with ketogenesis, fat reduction and sugar resistance functions and application thereof
CN110447892A (en) A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food
JP2011513458A (en) Medium chain dicarboxylic acid, its derivatives and metabolic disorders
CN106690331A (en) Kelp dietary fiber granules and preparation method thereof
AU2015310517A1 (en) Optimized nutrient food
CN102573523A (en) Health supplement food, feed, and pharmaceutical composition comprising chia seed and maca, and manufacturing method thereof
WO2018145664A1 (en) Anti-fatigue composition for use in improving endurance performance
CN108703364A (en) Treating fatty acid metabolism tailored version clinical nutrition formula and preparation method thereof
CN108685100A (en) A kind of compound small peptide powder formula and preparation method thereof
CN108175089A (en) A kind of full nutrient formulation liquid suitable for diabetic
CN108294306A (en) A kind of full nutrition special medicine purposes formula food of amino acid pattern
CN109730309A (en) Brain tonic and intelligence development tranquilizing the mind relieves stress fructus alpiniae oxyphyllae complex polypeptide nutrition element and preparation method
CN103190483A (en) Children growth promotion milk tea
US20160136124A1 (en) Administration of a food composition product
JP2008247748A (en) Nutritive composition for dialysis patient
CN110692884A (en) Probiotic health-care beverage assisting in reducing hypertension, hyperglycemia and hyperlipidemia
JP6301024B2 (en) Felicaribacterium spp.
CN108713755A (en) Quinoa weight reducing nutrition milk shake
JP2011004695A (en) Health food and health drink
JP6879297B2 (en) Composition for suppressing or ameliorating physical dysfunction or dysfunction associated with aging, or mental dysfunction or dysfunction associated with aging
JP2023154540A (en) Composition for preventing or improving age-related hearing loss

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201203

Address after: Plot 0501-57-4, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing 100176

Applicant after: Beijing Connaught Pharmaceutical Co.,Ltd.

Address before: Room 101, No. 7 Building, No. 2 District, 31 Kechuang Thirteenth Street, Beijing Daxing District, Beijing

Applicant before: Beijing Nuokangda Pharmaceutical Technology Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210621

Address after: Room 101, building 7, area 2, No.31, Kechuang 13th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing 100176

Applicant after: Beijing Nuokangda Pharmaceutical Technology Co.,Ltd.

Address before: Plot 0501-57-4, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing 100176

Applicant before: Beijing Connaught Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210810

Address after: 100176 room 108, first floor, building 7, zone 2, No. 31, Kechuang 13th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing (Yizhuang group, high-end industrial area of Beijing Pilot Free Trade Zone)

Applicant after: Beijing nuobao Nutrition Technology Co.,Ltd.

Address before: Room 101, building 7, area 2, No.31, Kechuang 13th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing 100176

Applicant before: Beijing Nuokangda Pharmaceutical Technology Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191115